| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Kapil Dhingra is Director at REPL. Kapil Dhingra's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider.
Kapil Dhingra has 18 Form 4 filings on record from July 2018 to June 2026, across 2 companies: Director at Black Diamond Therapeutics (BDTX), 2021–2026; Director at Replimune Group (REPL), 2018–2026.
The 22 reported transactions were 16 option or other derivative awards, 4 open-market sales and 2 option exercises.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $1.9M.
The largest open-market sale was 40,000 shares of REPL at an average $45.56 on December 7, 2020, about $1.8M.